Phagenesis

Phagenesis is a pioneering medical device company dedicated to advancing the treatment of dysphagia and improving patient outcomes. With a focus on innovation and clinical validation, Phagenesis has developed Phagenyx®, a groundbreaking neuromodulation system designed to restore swallowing control. This system is clinically proven to enhance swallowing safety and efficiency, leading to accelerated recovery from post-stroke dysphagia.

Phagenesis is committed to providing healthcare professionals with effective tools to address swallowing disorders. The company's dedication to research and development is evident in the extensive body of clinical evidence supporting Phagenyx®. The Phagenyx system enables early intervention, resulting in a 6-day faster return to oral nutrition, more than 2x improvement in swallowing safety, and 8 fewer days in the hospital.

Located at Enterprise House, Manchester, M15 6SE, GB, Phagenesis continues to drive advancements in dysphagia treatment, ensuring that patients receive the best possible care. We invite the manager of Phagenesis to create a customized and exclusive company showcase and product listing on our platform, further highlighting their innovative solutions and commitment to patient well-being.